Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu
NCT ID: NCT03789539
Last Updated: 2018-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
54 participants
INTERVENTIONAL
2018-06-02
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All subjects will receive an intramuscular (IM) injection twice,with a 21 days interval between treatments.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All subjects will receive an intramuscular (IM) injection twice,with a 21 days interval between treatments.
Subjects will undergo screening procedures within 6 days prior to first vaccination which will include medical history, vital signs, physical examination and safety blood and urine lab tests.
On the first treatment visit, eligible subjects will undergo pre-dose physical examination,vital signs, ECG, a blood sample will be drawn for circulating IgE. They receive an IM injection of either vaccine or placebo, according to the above treatment assignment, into the deltoid muscle. The subjects will remain under medical supervision for 72 hrs, after that time they will be released from the Clinical research center.
The second treatment will take place 21 days after the first vaccination. Procedures will be the same as on the first treatment visit.
Follow-up visits take place at 4th, 5th, 6th, 14th, 35th days. A Study Termination visit will take place at 42nd day of research. Adverse events (AEs) and changes in concomitant medications will be recorded, vital signs will be measured and the subjects will undergo physical examination and ECG. Blood and urine samples will be collected for safety.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
On the first treatment visit, eligible subjects will undergo pre-dose physical examination, ECG, vital signs, and a blood sample for circulating IgE. They will then receive an IM injection of either vaccine or placebo, according to the above treatment assignment, into the deltoid muscle preferably of non dominant arm. The subjects will remain under medical supervision for 72 hrs at which time they will be released from the Clinical research center.
The second treatment will take place 21 days after the first vaccination. Procedures will be the same as that of Visit 1 Additional follow-up visits will take place at 4-7th,14th,24-27th and 42nd days. Blood and urine samples will be collected for safety.
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LD Universal Influenza Vaccine Uniflu
low dose of Uniflu vaccine 0.5 ml (20 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
LD Universal Influenza Vaccine Uniflu
low dose Universal Influenza Vaccine Uniflu
HD Universal Influenza Vaccine Uniflu
high dose of Uniflu vaccine 0.5 ml (40 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
HD Universal Influenza Vaccine Uniflu
High dose Universal Influenza Vaccine Uniflu
Placebo
saline 0.5 ml
Placebo
Placebo saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LD Universal Influenza Vaccine Uniflu
low dose Universal Influenza Vaccine Uniflu
HD Universal Influenza Vaccine Uniflu
High dose Universal Influenza Vaccine Uniflu
Placebo
Placebo saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy that verificated by vital signs, physical examination, blood and urine lab tests
3. Body mass index (BMI) from 18.5 to 30.5 weight \>50 kg
4. Written informed consent.
5. Consent to the use of effective contraceptive methods throughout the study period.
6. Negative pregnancy test (for fertile women), consent to the use of effective contraceptive methods throughout the study period.
Exclusion Criteria
2. Vaccination within 6 months before the start of the study (including during participation in other clinical trials).
3. Symptoms of respiratory illness in the last 3 days.
4. Symptoms of any acute in the screening period.
5. Administration of immunoglobulins or other blood products for the last 3 months.
6. Taking immunosuppressive drugs and / or immunomodulators within 6 months before the start of the study.
7. Hypersensitivity or allergic reactions to the administration of any vaccine in medical history.
8. The presence of anaphylactic reactions, angioedema or other SAE to the administration of any vaccine in medical history.
9. Allergic reactions to vaccine components.
10. Seasonal allergy (at autumn period).
11. Acute or chronical desease or pathology from the gastrointestinal tract, liver, kidneys, cardiovascular system, central nervous system, musculoskeletal system, genitourinary and endocrine systems, which may influence the evaluation of the results of the study, in the anamnesis and also according to the screening examination data
12. Leukemia or any other blood disease or malignancy of other organs.
13. Thrombocytopenic purpura or bleeding disorders in medical history.
14. Seizures in medical history.
15. The presence or suspected presence of various immunosuppressive or immunodeficient state, including HIV infection.
16. Hepatitis B and C.
17. Tuberculosis.
18. Regular past or current use of narcotic drugs.
19. Pregnancy or breastfeeding.
20. Any conditions which may influence the evaluation of the results of the study, in the anamnesis and also according to the screening examination data.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Pharma Limited Liability Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia M Savateeva, PhD
Role: STUDY_DIRECTOR
VA Pharma Limited Liability Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Institute of Influenza
Saint Petersburg, Sankt-Peterburg, Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UIV-I-01/2017
Identifier Type: -
Identifier Source: org_study_id